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Purpose or Objective: To evaluate local control, 
enucleation-free survival, toxicity and cost-effectiveness in 
patients with choroidal melanoma treated with linac-based 
stereotactic radiosurgery (SRS). GammaKnife® radiosurgery 
has report very good results for this melanoma treatment.  
 
Material and Methods: Between 2003-2014, 6 patients with 
choroidal melanoma were treated at NISA Virgen del 
Consuelo Hospital in Valencia, Spain. Mean age was 59 years 
(range 43-79). Three were men and three women. Metastatic 
disease was ruled out in all cases. Two patients had small 
tumors, two medium sized lesions and two had large lesions 
according to Collaborative Ocular Melanoma Study 
Classification. Mean tumor volume was 0,49 cm3 (range 0,17-
0,93). Three tumors were localized in the right eye. Visual 
field previous to treatment was normal in 5 cases and one 
patient presented complete hemianopsia of the affected eye. 
Central vision was preserved in all cases. The procedure was 
made under sedation and retrobulbar blockage, the eye 
muscles were fixed to Leksell G-Frame with silk sutures. 
Magnetic resonance (MRI) and computed tomography (CT) 
were used to contour lesion. CTV minimal marginal dose is 30 
Gy, encompassed the 80 % isodose line in 4 patients and the 
60% and 55% isodose lines in the other cases. All were treated 
with 6 MV linac, one isocenter and cone-colimation. Global 
cost of this method is around 8.000 € (range 7.000-12.000). It 
is an ambulatory procedure with a total duration of 3 hours 
or less. 
 
Results: Median follow-up is 19 months (range 1-69). Follow 
up includes MRI and ophthalmoscopy every 6 months. 
Complete response in one patient, maximal partial response 
(≥ 50%) in three patients, partial response (≤ 50%) in other 
patient and it’s too early for response evaluation (less than 6 
weeks) in the last one. For lens and optic nerve, the dose 
constraints were 4 and 18 Gy, respectively. Up to date, no 
patient has local or distance progression. Enucleation has not 
been necessary in any patients. Five years after treatment 
one patient presented retinal scarring in irradiated area. 
Glaucoma start 9 month after SRS in one patient with 
previous cataract surgery. No other toxicities were observed.  
 
Conclusion: In our experience, linac SRS is effective eye and 
vision-sparing method to treat patients with a minimally 
invasive, safe and cost-efficient alternative to brachytherapy 
and enucleation in choroidal melanoma with high local 
control rates and low incidence of toxicities.  
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Purpose or Objective: The immunotherapy improves survival 
in patients (pts) with metastatic melanoma, but there is 
insufficient data on the efficacy in pts with brain metastases. 
SRS and SRT allow greater local control in pts with melanoma 
brain metastases, with not significant impact on prognosis. 
Our analysis evaluated survival and local control in pts 
treated with SRT/SRS with Cyberknife® system and 
Immunotherapy.  
 
Material and Methods: From November 2012 to September 
2015 we treated 47 pts (26 M and 21 F) with melanoma brain 
metastases. The median age was 59 years (28-81y). 28 pts 
received immunotherapy pre (pre-RT), concomitant and post 
radiation treatment (post-RT). 26 pts received Ipilimumab: 
14 pts pre-RT, 5 pts concomitant-RT, 7 pts post-RT; 2 pts 
received Nivolumab: 1 pt pre-RT and 1 pt concomitant-RT; 11 
pts received Pembrolizumab: 3 pts pre-RT, 4 pts concomitant 
RT, 4 pts post-RT. we treated 91 lesions of average size 13.5 
mm (2-36). Based on the number of lesions, size and 
location, 69 lesions were treated with SRS (10-24Gy), 22 with 
SRT (18-24Gy/2-3-5 fractions). We evaluated the local 
response according to RECIST criteria (complete response CR: 
disappearance of the lesion; partial response PR: at least a 
30% decrease in the diameter of lesion; progression disease 
PD: increase in the diameter of the lesion > 20%; stable 
disease SD: everyone else). We assessed overall survival, 
local control (LC) as the sum of CR, PR and SD, and the 
impact on LC of the association Radiotherapy (RT) and 
immunotherapy. 
 
Results: 41 pts were evaluable for follow-up (FU). The 6-
month survival was 58%. 11 patients died and 11 pts received 
Whole Brain RT for progression disease. At two months FU, of 
the 39 pts evaluable (24 treated with RT and 
immunotherapy), 85% had LC; at four months FU, of 29 pts 
evaluable (20 treated with RT and immunotherapy), 81% had 
LC; at six months FU, the 24 pts evaluable (15 treated with 
RT and Immunotherapy) 100% had LC. 
 
Conclusion: Our analysis seems to confirm the literature data 
in terms of overall survival. The results showed a good 
disease local control in pts treated with SRT/SRS and 
immunotherapy, demonstrating a potential role of 
immunotherapy in the treatment of melanoma brain 
metastases. the recruitment of a greater number of pts, a 
longer follow-up and new prospective studies of combination 
RT and immunotherapy are needed to demonstrate the 
immunotherapy role in the treatment of melanoma brain 
metastases. 
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Purpose or Objective: Adjuvant radiotherapy is proven to 
prevent lymph-node field relapse after therapeutic 
lymphadenectomy for melanoma, but does not improve 
overall survival. Risk factors for lymph-node field recurrence 
include presence of extracapsular extension, number and size 
of lymph nodes at dissection. This study reports patterns of 
failure in patients treated with adjuvant radiotherapy post 
lymphadenectomy for melanoma. 
 
Material and Methods: This retrospective study included all 
patients in three institutions treated with adjuvant 
radiotherapy post lymphadenectomy for melanoma between 
June 2012 and March 2015. 
Patients who received radiotherapy were those with high risk 
of lymph node field recurrence, as per the findings of 
Burmeister et al in 2012. Patients received radiotherapy to 
the head & neck (55%), groin (30%) and axilla (15%). All were 
staged with PET or CT. Both IMRT (50%) and 3D conformal 
(50%) techniques were used. 
 
Results: 20 patients were treated during this period (see 
table). Median follow up was 16 months (range 6.7 - 32 
months).  
There were no lymph node field recurrences. 
Local recurrence rate was 10%. 
Distant recurrence rate was 35%, all occurring within 4 
months from completion of radiotherapy.  
Distant recurrence rate was 53.8% in patients with 
extracapsular extension. 
All patients with local or distant relapse had extracapsular 
extension. 
71% of patients with distant recurrence had PET staging. 
8% of patients experienced grade 3 radiotherapy toxicity. 
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Age Primary Adjuvant RT region 
No of 
positive 
nodes 
ECE Site of recurrence 
Time to 
recurrence 
post RT 
Mortality 
post 
recurrence 
64 Neck Neck 6/61 No - - - 
57 Unknown Neck 1/29 Yes - - - 
81 Cheek Neck 2/31 Yes Distant 4 months RIP at 4 months 
43 Leg Groin 9/25 No - - - 
41 Back Axilla 3/16 No - - - 
19 Neck Neck 1/35 Yes Distant 1 month Alive at 25months 
79 Eyelid Neck 1/58 Yes Local + Distant 3.5 months 
Alive at  
22months 
69 Auricular Neck 4/50 Yes - - - 
68 Unknown Neck 1/64 Yes - - - 
65 Cheek Neck 1/24 No - - - 
75 Unknown Neck 4/45 Yes Distant 4 months RIP at 1 month 
73 Neck Neck 0 No - - - 
62 Leg Groin 5/10 No - - - 
70 Leg Groin 13/33 No - - - 
57 Foot Groin 3/8 Yes Local + Distant 
0 months + 
2.8 months 
RIP at 
10months 
80 Cheek Neck 38/42 Yes Distant 1 month RIP at 7months 
48 Unknown Axilla 13/33 Yes - - - 
57 Hand Axilla 13/33 Yes Distant 2 months Alive at 8months 
63 Leg Groin 2/25 Yes - - - 
37 Leg Groin 1/9 Yes - - - 
 
Conclusion: Radiotherapy was well tolerated and effective as 
no patient developed lymph node field relapse. However 
patients are at risk of early local and distant relapse, 
especially those with extranodal extension. Consideration 
should be given to the use of routine PET CT for high risk 
patients.  
 
Electronic Poster: Clinical track: Sarcoma  
 
 
EP-1398 
Acute gastro-intestinal toxicities after pre-operative 
tomotherapy for retroperitoneal liposarcoma 
P. Sargos
1Institut Bergonié, Radiotherapy, Bordeaux, France 
1, B. Henriques de Figueiredo1, C. Kintzinger1, E. 
Stoeckle2, M. Delannes3, G. Ferron3, A. Giraud4, C. Dupouy4, 
M.A. Mahé5, A. Mervoyer5, M. Antoine6, B.N. Bui7, C. Bellera4, 
G. Kantor1 
2Institut Bergonié, Surgery, Bordeaux, France 
3Institut Universitaire du Cancer Toulouse Oncopole, 
Radiotherapy, Toulouse, France 
4Institut Bergonié, Clinical and Epidemiology Research Unit, 
Bordeaux, France 
5Institut de Cancérologie de l'Ouest, Radiotherapy, Nantes, 
France 
6Institut Bergonié, Physics Unit, Bordeaux, France 
7Institut Bergonié, Medical Oncology, Bordeaux, France 
 
Purpose or Objective: Surgery is the cornerstone in the 
management of sarcomas. The aim of this study was to 
evaluate intensity-modulated radiotherapy (RT) with 
tomotherapy followed by surgery in terms of acute gastro-
intestinal (GI) toxicities, especially regarding the high-level 
of prescribed dose (54 Gy/30 fractions/6weeks). 
 
Material and Methods: From April 2009 to September 2013, 
48 patients were included in a prospective multicenter study. 
Feasibility of tomotherapy, acute toxicities and local control 
at 3 years were the principal and secondary objectives. 
Inclusion criteria were operable, biopsy-proven, 
retroperitoneal liposarcoma. Patients with non-operable 
tumors validated after multi-disciplinary team evaluation, 
other histology or metastatic disease were excluded.Clinical 
Target Volume (CTV) and mains organs at risk (contralateral 
kidney, duodenum, bowel bag) were systematically 
delineated with the surgeon. Dose constraints to the bowel 
bag were defined as V45 Gy<33% and V30 Gy<50%. Surgery 
was planned 4 to 8 weeks after RT. Clinical visits were 
performed weekly during RT, before surgery, and 2 and 6 
months after surgery. Toxicity was recorded according to 
CTCAE V4.0 scale. 
 
Results: For acute GI toxicity, 46/48 patients were 
evaluable. All patients completed the radio surgical schedule 
without dose reduction. Mean age was 62 years (36-82). All 
patients were OMS≤2 except one (OMS=3). Mean CTV was 
2954 cc (920-4989. Mean small bowel and duodenal volumes 
were 2725 (1355-4090) and 73 cc (33-113), respectively. 
Monobloc exerese was systematically achieved and all 
patients underwent homolateral nephrectomy. Twenty-nine 
patients underwent bowel resection, including large bowel 
(28/29), small bowel(4/29) and duodenum (1/29). Mean 
weight loss during RT was 5,4 kg (about 8% of mean body 
weight) and 8,9 kg at the first visit after surgery. At 2 
months, grade 3 toxicities included duodenal stenosis (1/46), 
intestinal fistula (1/46) and enterocolitis (1/46) and grade 4 
toxicity included GI fistula (1/46). At 6 months, no GI 
toxicities were observed. Three patients died within 6 
months after surgery, 2 of which were related to treatment: 
one respiratory disorder 6 days after surgery and 1 duodenal 
perforation with necrosis and infection 4 months after 
surgery. 
 
Conclusion: For patients with retroperitoneal liposarcoma, 
preoperative 54 Gy RT appears feasible. Due to the low rate 
of severe complications, no statistic correlations with dose in 
digestive structure were performed. 
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Purpose or Objective: The standard treatment of high grade 
soft tissue sarcoma (STS) is surgery followed by adjuvant 
radiotherapy (RT); chemotherapy (CT) can be an option in 
selected patients due to reported benefit in terms of disease 
free survival. The association of RT with CT might increase 
tissue reactions with the consequent risk of unplanned 
treatment interruptions resulting in an increased risk of 
treatment failure. This retrospective study analyze the safety 
and feasibility, respectively in terms of additional toxicity 
and compliance, of concurrent chemoradiotherapy (CTRT) in 
adjuvant treatment of STS.  
 
Material and Methods: Data of 84 STS patients treated with 
surgery and adjuvant RT from June 1994 to November 2014 at 
the University of Florence, were retrospectively collected. 
Anthracycline-based CT was performed in high risk patients. 
Acute and late local toxicity of RT treatment were assessed 
respectively by Common Terminology Criteria for Adverse 
Events (CTCAE) 4.0 and RTOG/EORTC criteria for the Late 
Radiation Toxicity. CT-related hematological Toxicity was 
assessed by CTCAE 4.0. 
 
Results: Twenty-four (28.6%) patients received CTRT. Mean 
follow-up was 5.6 years (range 0.4-18.8). At the time of our 
analysis 8 (9,5%) patients had a local relapse, 17 (19.8%) 
developed distant metastases, and 14 (16.7%) died of 
metastatic disease. Local Recurrence Free Survival (LRFS), 
Distant Relapse Free Survival (DRFS) and Overall Survival (OS) 
were respectively 83.4%, 70% and 69.5%. Grade ≥3 leucopenia 
occurred in 6 CTRT patients, resulting in early interruption of 
the CT treatment in 3 cases. Skin acute toxicity was 
developed in 59 (70,2%) of patients ; G3 skin toxicity 
occurred in 19 (22.6%) cases and determined treatment 
interruption in 15 (17.9%) patients with a mean treatment 
